IDH1 and myelodysplastic syndrome: Other IDH inhibitors in clinical trials are Bayer’s BAY1436032 for IDH1 mutant solid tumors (NCT02746081), Forma Therapeutics’s FT-2102 (Compound 26) for AML/MDS as a single agent (phase 1) and in combination with azacytidine (phase 2) are in clinical trials (NCT02719574).